Citation tools
"64Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor-Positive Neuroendocrine Tumors: Results of the First US Prospective, Reader-Blinded Clinical Trial." Journal of Nuclear Medicine
(2020):
jnumed.119.236091.
Web. 25 May. 2025.